Trial Profile
A Phase II Single Arm Trial of Adding Simvastatin to Dual Anti-HER2 Therapy in Patients With HER2-Positive Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Simvastatin (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- Acronyms SIMPHONY
- 11 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 01 Apr 2022 Planned End Date changed from 1 Dec 2025 to 1 Dec 2030.
- 01 Apr 2022 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2028.